Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.

The company reported quarterly losses of 93 cents per share which missed the analyst consensus estimate of losses of 80 cents per share. The company reported quarterly sales of $9.325 million which beat the analyst consensus estimate of $6.044 million.

“We have made significant progress across our business this year, including the rapid enrollment of 162 patients into the Phase 3 EMPEROR study and progression of these patients through key study milestones with the first patients now approaching the end of the 52-week treatment period,” said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. “With no treatment discontinuations to date in EMPEROR, and supportive four-year safety and efficacy data from the ongoing open-label extension studies, we have confidence in the potential of zorevunersen to change the course of Dravet syndrome. We look forward to our upcoming pre-NDA meeting with the FDA to align on the overall data package content and timing, as well as the statistical analysis plan, as we prepare to initiate our rolling U.S. NDA submission in the first quarter of 2027.”

Stoke Therapeutics shares closed at $29.56 on Monday.

These analysts made changes to their price targets on Stoke Therapeutics following earnings announcement.

  • Canaccord Genuity analyst Sumant Kulkarni maintained the stock with a Buy and lowered the price target from $60 to $58.
  • Wedbush analyst Laura Chico maintained the stock with an Outperform rating and raised the price target from $38 to $40.

Considering buying STOK stock? Here’s what analysts think:

Photo via Shutterstock